← Eichor
Study identifier: NCT07294014 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Investigation of Medial Longitudinal Arch and Foot Function in Patients With Lipedema

Condition: Lipedema · Hypermobility Syndrome (Disorder) · Pes Planus  ·  Sponsor: Marmara University

PhaseN/A
Planned participants32
Who can joinFemale, 18 Years to 65 Years
Healthy volunteersYes

About this study

Lipedema is a chronic adipose tissue disorder that commonly leads to joint laxity, hypermobility, and functional limitations, yet its impact on foot morphology has not been systematically examined. This case-control study aims to investigate whether patients with lipedema exhibit a higher prevalence of generalized joint hypermobility and foot structural abnormalities-specifically pes planus-compared with age- and BMI-matched controls. Using radiographic measurements (Meary angle and calcaneal inclination angle), clinical hypermobility assessment, and validated functional scales, the study seeks to determine the relationship between lipedema, hypermobility, and foot function.

This description comes directly from the study's public registry record.

Talk to the study team

Gökçenur Yalçın, M.D., PMR Specialist  ·  +90 216 414 05 45  ·  gokce_cihaner@hotmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Marmara University Pendik Training and Research HospitalIstanbul, Turkey (Türkiye)Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07294014